Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Eli Lilly's weight loss drug Zepbound is now available at US pharmacies
12:42pm, Tuesday, 05'th Dec 2023
Eli Lilly and Co (NYSE:LLY) announced that its weight loss drug Zepbound is now available at pharmacies in the US, sending its shares slightly higher Tuesday. The treatment is expected to cost $25 p
Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the
Eli Lilly's obesity drug now available in U.S. pharmacies
08:09am, Tuesday, 05'th Dec 2023
Eli Lilly's recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker
Eli Lilly's new obesity drug Zepbound added to major PBM formularies as it hits pharmacy shelves
08:05am, Tuesday, 05'th Dec 2023
Eli Lilly & Co. LLY, +0.28% said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit manager's preferred formulary, or list of covered drugs, as it hits U.S. pharmacy shel
No more exercising? President RFK Jr.?
05:45am, Tuesday, 05'th Dec 2023
Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels wil
Alzheimer's Disease Drug Development: Another Lost Year
03:58am, Tuesday, 05'th Dec 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of
Ozempic vs. Mounjaro:: Battle of the bulge
10:16am, Monday, 04'th Dec 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
09:00am, Monday, 04'th Dec 2023
Modern portfolio theory offers investors some important guidelines for picking the best potential dividend stocks. Eli Lilly meets all of the theory's most important guideposts.
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
07:43am, Monday, 04'th Dec 2023
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
07:21am, Monday, 04'th Dec 2023
Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the rad
3 No-Brainer Growth Stocks to Buy in December
06:54am, Sunday, 03'rd Dec 2023
Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
05:53am, Saturday, 02'nd Dec 2023
Lilly's Mounjaro and Zepbound appear to have an efficacy advantage over Novo Nordisk's Ozempic and Wegovy. Lilly also has a stronger product lineup and pipeline outside of the diabetes and obesity ind
5 Top Stocks to Buy Before 2024
05:00am, Saturday, 02'nd Dec 2023
Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- ar
US FDA gives second approval to Eli Lilly's drug for type of blood cancer
06:18pm, Friday, 01'st Dec 2023
Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer.
There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
12:22pm, Friday, 01'st Dec 2023
Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, an
